pharmacist holding Narcan nasal spray

Our Mission

Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant is best known for its contribution to the formulation of the first FDA-approved, user-friendly nasal naloxone spray.  In 2015 this product, NARCAN® Nasal Spray 4mg, became available in the United States and Canada through our licensee, Adapt Pharma (now a part of Emergent BioSolutions). Opiant is now focused on advancing its pipeline.

Mission, Vision, and Values

We are developing medicines for addictions and drug overdose.

Our clinical pipeline includes a nalmefene nasal spray to better address opioid overdoses, particularly those that are fentanyl-related.

We are working to advance OPNT002, nasal naltrexone for Alcohol Use Disorder.

We are further working to advance two preclinical programs.  At the end of 2018, we in-licensed drinabant, a CB-1 antagonist, from Sanofi for Acute Cannabinoid Overdose, a growing issue that directly correlates with increased cannabis legalization, especially for recreational use.

Company Evolution Timeline

  1. 2009

    2009 – 2012

    • Changed name from Madrona Ventures to Lightlake Therapeutics
    • Focused on evaluating naloxone’s potential in the treatment of binge eating disorder
  2. 2013

    2013 – 2014

    • Entered into a collaboration with NIDA to develop intranasal naloxone for reversal of opioid overdose
    • Executed a global licensing agreement with Adapt Pharma in exchange for development and sales milestones plus royalties
    • Established a research license with Aegis Therapeutics for its proprietary delivery enhancement agent, Intravail®
  3. 2015

    2015 – 2017

    • NARCAN® Nasal Spray approved by the FDA
    • Changed name from Lightlake Therapeutics to Opiant Pharmaceuticals
    • Licensed heroin vaccine from Walter Reed for Opioid Use Disorder (OUD)
    • Initiated OPNT001 Phase 2 study of nasal naloxone in Bulimia Nervosa
    • Uplisted to NASDAQ as $OPNT
  4. 2018

    2018 – 2019

    • Announced Nasal Nalmefene program with positive Phase 1 data for OPNT003, a long-acting opioid antagonist for opioid overdose
    • Entered manufacturing agreement with Consort Medical for OPNT003
    • Received funding from the NIH and BARDA to fuel OPNT003 research & development activities
    • Awarded grant from Walter Reed to develop OPNT005, a heroin vaccine for OUD
    • Expanded into acute cannabinoid overdose (ACO) through an exclusive global licensing agreement with Sanofi for OPNT004, drinabant
    • Discontinued OPNT001 program evaluating naloxone in the treatment of Bulimia Nervosa
    • Published clinical data in support of OPNT002, nasal naltrexone, for on-demand treatment of alcohol use disorder (AUD)
    • Widened partnership with Sanofi through manufacturing agreement for OPNT004
  5. 2020

    2020 – 2021

    • Announced development collaboration with National Center for Advancing Translational Sciences (NCATS) to advance OPNT004 for ACO
    • Partnered with Aptar Pharma for unit dose delivery system for OPNT003, nasal nalmefene
    • Received additional BARDA funding for OPNT003, nasal nalmefene, development program
    • Announced positive Phase 2 confirmatory pharmacokinetic (PK) top-line results for study of OPNT003, nasal nalmefene
    • Obtained FDA Fast Track designation for OPNT003, nasal nalmefene
  6. 2022

    2022 – Present

    • Dosed first patient in Phase 2 trial of OPNT002, nasal naltrexone, for AUD
    • Received additional BARDA funding for OPNT003, nasal nalmefene, development program
    • Announced positive Phase 2 pharmacokinetic (PK), safety and tolerability top-line results for multi-dose study of OPNT003, nasal nalmefene
    • Announced positive topline results from head-to-head pharmacodynamic study comparing OPNT003, nasal nalmefene, to 4mg nasal naloxone
    • Initiated rolling submission of New Drug Application to U.S. Food and Drug Administration for OPNT003 for the treatment of opioid overdose
    • Announced Notice of Allowance for U.S. patent with claims covering OPNT003 for the treatment of opioid overdose
    • Announced Notice of Allowance for U.S. Patent with claims covering OPNT004 for the treatment of cannabinoid hyperemesis syndrome